心脏缩:从病理生理机制到心力衰竭 发育
Alfredo Caturano1, Erica Vetrano1, Raffaele Galiero1
1Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", I-80138 Naples, Italy.
Reviews in cardiovascular medicine
|July 30, 2024
概括
心脏缩是对心脏工作量增加的反应,可以导致心力衰竭. 了解其分子机制是开发新疗法的关键,以预防和逆转这种情况.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 病理生理学 病理生理学
背景情况:
- 心脏缩是对工作量增加的适应性反应,旨在减少心室壁压力.
- 持续的刺激会导致病理性缩,导致心力衰竭,功能障碍和死亡率增加.
- 糖尿病心肌病包括由胰岛素抵抗,高血糖和相关的代谢和炎症变化驱动的病理性缩.
研究的目的:
- 审查病理性心脏缩背后的分子机制.
- 探索这些机制是如何导致糖尿病心肌病症等疾病的.
- 确定预防和逆转心脏缩的潜在治疗点.
主要方法:
- 在病理性心脏缩中的分子机制的文献综述.
- 分析病理生理路径,包括细胞死亡,纤维化和代谢变化.
- 检查胰岛素抵抗和高血糖在糖尿病心肌病中的作用.
主要成果:
- 病理性缩涉及复杂的机制:细胞死亡,纤维化,线粒体功能障碍,新陈代谢改变,质量控制受损.
- 胎儿基因的重新激活,瘤的失调和不充分的血管生成是关键特征.
- 糖尿病心肌病症强调了代谢失调对心脏重塑的影响.
结论:
- 了解病理性缩的分子基础对于治疗的发展至关重要.
- 针对特定的途径可以提供治疗和预防心力衰竭的新策略.
- 干预措施可以专注于代谢纠正,改善蛋白质/线粒体质量,调节炎症反应.
相关概念视频
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Pathophysiology of Cardiac Performance
624
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
624
Heart Failure Drugs: Diuretics
355
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
355
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
413
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413
Heart Failure Drugs: β-Blockers
332
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
332


